The pharmaceutical industry’s advancements in the development of biologics, a class of medications, have expanded the range of treatable disease conditions, but at extremely high costs and insurance copays. This post focuses on a concerning aspect of manufacturer copay programs – initiatives designed to help cover insurance copays associated with biologic treatments. Specifically, we will examine copay program agreement of Sandoz and raise concerns about patient privacy and medical information sharing.

Continue reading Biologics and Biosimilar Treatment: Sell Your Data or Sell Your Kidney? →